Perseus Proteomics, Inc. (JP:4882)
:4882
4882 Stock Chart & Stats
¥220.00
-¥14.00(-2.34%)
At close: 4:00 PM EST
¥220.00
-¥14.00(-2.34%)
Day’s Range― - ―
52-Week Range¥203.00 - ¥586.00
Previous CloseN/A
Volume686.20K
Average Volume (3M)226.58K
Market Cap
¥3.74B
Enterprise Value¥2.19B
Total Cash (Recent Filing)¥1.51B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-11.42
Shares Outstanding16,999,600
10 Day Avg. Volume184,610
30 Day Avg. Volume226,583
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.33
Price to Sales (P/S)87.24
P/FCF Ratio-13.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-62.5
Revenue Forecast (FY)¥120.00M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsVery high and consistent gross margins indicate strong unit economics and pricing power for the firm’s core proteomics products and services. Over a multi-month horizon this supports margin scalability as revenue expands, making future operating leverage plausible if SG&A growth is controlled.
Debt-free Balance SheetA zero-debt capital structure materially reduces refinancing risk and fixed interest costs, preserving flexibility for R&D or strategic investment. This gives management optionality to raise capital on favorable terms or withstand cash volatility without near-term debt maturities pressuring operations.
Consistent Revenue GrowthSustained revenue growth over several years shows market traction for the company’s proteomics offerings and a growing customer base. While current scale is limited, persistent top-line expansion supports a path to leverage the company’s high gross margins into improved operating performance as fixed costs are absorbed.
Bears Say
Deep And Persistent LossesExtremely negative net margins reflect a cost structure far larger than current revenue and indicate that profitability is not near-term. Unless operating expenses are materially reduced or revenue scales meaningfully, sustained losses will continue to erode equity and limit reinvestment capacity over the next several months.
Chronic Cash BurnPersistent negative operating and free cash flows show the business consumes real cash rather than reporting only non‑cash losses. This structural cash burn requires ongoing external funding and reduces runway, raising the probability of dilution or constrained investments unless cash generation materially improves.
Declining Equity And Negative ROEFalling equity alongside strongly negative ROE signals capital destruction: investments are not producing returns and shareholders are being diluted or written down. Over a multi-month horizon this heightens financing risk and the need for corrective strategy or capital injections to stabilize the balance sheet.
Perseus Proteomics, Inc. News
4882 FAQ
What was Perseus Proteomics, Inc.’s price range in the past 12 months?
Perseus Proteomics, Inc. lowest stock price was ¥203.00 and its highest was ¥586.00 in the past 12 months.
What is Perseus Proteomics, Inc.’s market cap?
Perseus Proteomics, Inc.’s market cap is ¥3.74B.
When is Perseus Proteomics, Inc.’s upcoming earnings report date?
Perseus Proteomics, Inc.’s upcoming earnings report date is May 08, 2026 which is in 36 days.
How were Perseus Proteomics, Inc.’s earnings last quarter?
Perseus Proteomics, Inc. released its earnings results on Feb 13, 2026. The company reported -¥11.42 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.42.
Is Perseus Proteomics, Inc. overvalued?
According to Wall Street analysts Perseus Proteomics, Inc.’s price is currently Overvalued.
Does Perseus Proteomics, Inc. pay dividends?
Perseus Proteomics, Inc. does not currently pay dividends.
What is Perseus Proteomics, Inc.’s EPS estimate?
Perseus Proteomics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Perseus Proteomics, Inc. have?
Perseus Proteomics, Inc. has 16,999,600 shares outstanding.
What happened to Perseus Proteomics, Inc.’s price movement after its last earnings report?
Perseus Proteomics, Inc. reported an EPS of -¥11.42 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.966%.
Which hedge fund is a major shareholder of Perseus Proteomics, Inc.?
Currently, no hedge funds are holding shares in JP:4882
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Perseus Proteomics, Inc.
Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell; and PPMX-T004, an antibody drug conjugate. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Technical Analysis
Trans Genic Inc.
―
Cosmo Bio Co., Ltd.
―
ReproCELL Inc.
―
Human Metabolome Technologies, Inc.
―
Precision System Science Co.,Ltd
―
Options Prices
Currently, No data available
---